Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 3Completed 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Leukemia 1Immunoglobulin Light-chain Amyloidosis 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 11Rituximab 10Gemcitabine 9Paclitaxel 7Lenalidomide 7Decitabine 7Cytarabine 7Bendamustine Hydrochloride 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Carboplatin 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Antilymphocyte Serum 4tislelizumab 3pomalidomide 3liposomal doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Recurrence × dexamethasone acetate × Clear all
NCT05052970 2022-02-01

Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase 1 Unknown
60 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡